Clinical Trial

Insulin Regulation of Lipolysis and Lipolysis Proteins

Study Description

Insulin Regulation of Lipolysis and Lipolysis Proteins

These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid metabolism.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Behavioral - Immediate weight loss

Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

Drug - Pioglitazone

Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.

Behavioral - Deferred weight loss

Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.

Drug - Placebo

Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.

Additional Information

Official Study Title

Insulin Regulation of Lipolysis and Lipolysis Proteins

Clinical Trial ID

NCT03866408

ParticipAid ID

bqxoDa